

UC Davis

UC Davis Previously Published Works

Title

Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer.

Permalink

<https://escholarship.org/uc/item/95n974tb>

Journal

Cancer research, 80(21)

ISSN

0008-5472

Authors

Przanowski, Piotr
Lou, Song
Tihagam, Rachisan Djiake
et al.

Publication Date

2020-11-01

DOI

10.1158/0008-5472.can-20-1459

Peer reviewed



Published in final edited form as:

Cancer Res. 2020 November 01; 80(21): 4791–4804. doi:10.1158/0008-5472.CAN-20-1459.

Oncogenic TRIM37 links chemoresistance and metastatic fate in triple-negative breast cancer

Piotr Przanowski^{1,a}, Song Lou^{1,a}, Rachisan Djake Tihagam¹, Tanmoy Mondal¹, Caroline Conlan¹, Gururaj Shivange¹, Ilyas Saltani¹, Chandrajeet Singh¹, Kun Xing¹, Benjamin B. Morris¹, Marty W. Mayo^{1,3}, Luis Teixeira^{4,5}, Jacqueline Lehmann-Che^{4,5}, Jogender Tushir-Singh^{1,3,6,*}, Sanchita Bhatnagar^{1,2,3,6,*}

¹Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

²Department of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

³UVA Cancer Center, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

⁴University of Paris, HIPI INSERM U976, F-75010 Paris, France

⁵Breast Diseases Unit and Molecular Oncology Unit, AP-HP, Hospital Saint Louis, F-75010 Paris, France

⁶Lead Contact

Abstract

The majority of clinical deaths in TNBC patients are due to chemoresistance and aggressive metastases, with high prevalence in younger women of African ethnicity. While tumorigenic drivers are numerous and varied, the drivers of metastatic transition remain largely unknown. Here, we uncovered a molecular dependence of TNBC tumors on the TRIM37 network which enables tumor cells to resist chemotherapeutic as well as metastatic stress. TRIM37-directed histone H2A monoubiquitination enforce changes in DNA repair that rendered TP53-mutant TNBC cells resistant to chemotherapy. Chemotherapeutic drugs triggered a positive feedback loop via ATM/E2F1/STAT signaling, amplifying the TRIM37 network in chemoresistant cancer cells. High expression of TRIM37 induced transcriptomic changes characteristic of a metastatic phenotype, and inhibition of TRIM37 substantially reduced the *in vivo* propensity of TNBC cells. Selective delivery of TRIM37-specific antisense oligonucleotides using anti-folate receptor 1-conjugated nanoparticles in combination with chemotherapy suppressed lung metastasis in spontaneous metastatic murine models. Collectively, these findings establish TRIM37 as a clinically relevant target with opportunities for therapeutic intervention.

*To whom correspondence should be addressed: Sanchita Bhatnagar, Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, 1340 Jefferson Park Ave, Pinn Hall 6044, Charlottesville, VA 22908, USA. Tel: 434-982-6441. sb5fk@virginia.edu.; Jogender Tushir-Singh, Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, 1340 Jefferson Park Ave, Pinn Hall 6047, Charlottesville, VA 22908, USA. Tel: 434-982-0465. js2yr@virginia.edu.

^aThese authors contributed equally to the manuscript

Competing interests: Authors include no conflict of interest.

Introduction

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that accounts for ~20% of all breast cancer cases with the annual incidence rate in the United States estimated to be 40,000 (1). TNBC patients are disproportionately associated with the highest frequency of chemoresistance, relapse, and metastasis. Consequentially, the 5-year survival rate of TNBC is 77% relative to 93% for other breast cancer subtypes (1). Despite the high mortality rate in women worldwide, chemotherapy remains the standard of care for TNBC patients. Although chemotherapy is effective initially in TNBC patients, it is often accompanied by resistance, relapse, and severe side effects. Therefore, new and effective targeted therapies to prevent and ultimately cure TNBC are a clinical priority. While lifestyle, epidemiologic, and cultural factors shape TNBC clinical outcome, the disease etiology is also dependent on biogeographical ancestry (2). Thus, lack of targeted therapies for TNBC is fraught with multiple challenges attributed to limited understanding of genetic complexities, metastatic biology, and drivers of metastatic traits.

An unresolved question in cancer biology is what drives a primary tumor to become metastatic? This is a clinically relevant question because metastatic, not primary tumors, are fatal. In general, numerous oncogenes and tumor suppressors are genetically or epigenetically altered in cancer and accumulate during tumorigenesis. But whether drivers of tumorigenesis are also the causal factor of the metastatic transition remains to be addressed. To this end, extensive transcriptomic and genetic scans of evolving carcinomas revealed mutations that were represented in premalignant biopsies but not in tumor biopsies, suggesting divergence of genetic alterations during the transition from primary to regional metastases (3,4). Additionally, dynamic epigenetic mechanisms are also intimately linked to metastatic transitions (5,6). For example, TNBC tumors harbor a high frequency of hypermethylated promoters in commonly targetable drivers, such as *TP53*, *BRAF*, *KRAS*, and *EGFR* (7). Alterations in epigenetic factors causing neomorphic mutations (e.g., *EZH2*, *DNMT3A*) or translocations (e.g., *NSD2*, *MMSET*) are also frequent in cancer patients (6). As such, several small molecules targeting epigenetic regulators have entered clinical trials, for example, Estinosat, Belinostat, and Panobinostat (8). Understandably, these drug treatments are not mutation-specific and thus, pose a significant toxicity risk to untransformed cells, underscoring the critical need for targeted therapies.

We have originally described tripartite motif-containing protein 37 (TRIM37) as a breast cancer oncoprotein that can epigenetically silence tumor suppressors (9,10). Clinically, high-TRIM37 associate with poor overall survival (9). Mechanistically, TRIM37 mono-ubiquitinates histone H2A at Lys119 (H2Aub) to down-regulate target genes (9). Functionally, TRIM37 over-expression renders non-transformed breast cells tumorigenic, and inhibition of TRIM37 function reduces tumor growth (9). While TRIM37 promotes tumorigenesis, its function in breast cancer metastasis and the therapeutic implications of TRIM37 targeting remain to be demonstrated.

Metastasis is a multistep process that includes pathways regulating the epithelial-mesenchymal transition, infiltration of distant sites, and metastatic growth (11). Given the majority of TNBC patients receive chemotherapy, the ability to resist therapy-induced cell

death is perhaps the first step towards a metastatic phenotype. Indeed, recent evidence revealed synchronized expression of genes involved in surviving the stress of chemotherapy as well as overcoming the natural barriers of metastatic growth. For example, a CXCL1/2 paracrine pathway (12) and *MTDH* (13) were recently identified with dual functionality in metastasis and chemoresistance. Here, we uncover that TRIM37 alters DNA damage response to prevent therapy-induced cell death, and enforces a transcriptional program favoring metastasis. In particular, we report that selective TRIM37 inhibition in TNBC tumors suppress lung metastases *in vivo*. Together, these data reveal that TRIM37 is a new epigenetic driver of aggressive TNBC biology, which can be targeted to simultaneously increase chemotherapy efficacy and reduce metastasis risk in TNBC patients.

Materials and Methods

Cell lines and cell culture

MDA-MB-231-luc-D3H2LN-BMD2b (provided by Takahiro Ochiya), MDA MB 231, MDA MB 468 and HCC1806 (provided by Michael J. Lee) cells were maintained in RPMI medium supplemented with 10% fetal bovine serum (FBS, Invitrogen) at 37°C and 5% CO₂. MCF10A, MCF7, MCF10AT, HCC1806RR (provided by Sophia Ran) and TP53^{-/-}-MCF10A (provided by David Weber and Michele Vitolo) were cultured as described previously (9,14,15). Cells cultured at the same time were pooled together and then seeded after counting in a 6-well or 10-cm dish. Cells were then subjected, in a random order, to treatment with a control or test different biologics, which included shRNA, sgRNA, vectors, and small molecule inhibitors. Cells were routinely tested for mycoplasma using Plasmotest kit from (Invivogen).

Animal Care

NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ and Balb/cJ (Jackson Laboratory) were housed in a specific-pathogen-free facility accredited by the American Association of Laboratory Animal Care. All animal studies were approved (#4112 and #4222) by the Institutional Animal Care and Use Committee.

CRISPR/Cas9 targeting

The *Gapdh* sgRNAs were cloned in pLentiCrispr v2 plasmid (Addgene) and packaged into virus as recommended by the manufacturer. Cells were infected with packaged virus as described previously (9).

Recombinant Antibody Cloning

Farletuzumab (anti-human FOLR1) and LK26 (anti-mouse FOLR1) antibodies were cloned, engineered, expressed, and purified as described previously (16). To generate an antibody conjugate platform for nanoparticles linkage, a novel linker sequence [(X)₃Cys(X)₃ amino acid sequence] was engineered in continuation of the carboxy terminal of heavy chain (called Fc-Linkered). The knob chain is exactly similar to hole chain except for the presence of this unique cysteine residue.

Recombinant Antibody Expression

Free style CHO-S cells (Invitrogen) were cultured and maintained according to supplier's recommendations (Life technologies). A ratio of 2:1 (light chain, V_L ; heavy chain, V_H) DNA was transfected using 1 mg/ml polyethylenimine and cultured at 37°C. After 24 hrs., transfected cells were cultured at 32°C for additional 9 days. Cells were fed every 2nd day with 1:1 ratio of Tryptone feed and CHO Feed B and antibodies were purified as described previously (16). An Autodesk Inventor Professional 2020 was used to draw the design of antibody.

Nanoparticle synthesis and packaging

Cholesterol, 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide-(polyethyleneglycol-2000)] ammonium salt (DSPE-PEG2000-Maleimide) were purchased from Avanti Polar Lipids, Inc. (Alabaster).

TRIM37-ASO (IDT) and control-ASO (IDT) loaded bilayer nanoparticles were prepared as previously described with modification (17). Briefly, 150mM CaCl_2 with 0.5mM ASO were dispersed in Cyclohexane/Igepal CO-520 (70:30 v/v) solution to form water-in-oil reverse micro-emulsion (Solution A). The phosphate phase was prepared by mixing 1.5 μM NaHPO_4 (pH=9.0) and 6.9 μM DOPA in Cyclohexane/Igepal CO-520 (70:30 v:v) solution (Solution B). Calcium phosphate-alginate (CaP) core was prepared by mixing Solutions A and B. For assembly of outer leaflet, CaP core was mixed with 0.5 μM DOTAP/Cholesterol (1:1), and 0.15 μM DSPE-PEG-2000-Maleimide. CaP-bilipids nanoparticles were mixed with 0.56 μM engineered *Farletuzumab* solutions and incubated overnight at 4°C. Finally, CaP-bilipids nanoparticles were sterile filtered for subsequent experiments. An Autodesk Inventor Professional 2020 was used to draw the design of smart nanoparticle.

NSG tumor xenograft studies

For indicated cell lines, weight and aged matched female NSG mice were injected subcutaneously with 2×10^6 TNBC cells in their right flank as described previously (9). For *in vivo* Dox-induced TRIM37 upregulation studies, mice bearing $\sim 200 \text{ mm}^3$ HCC1806 tumors weight matched animals were randomly assigned into groups and injected with 2 mg/kg Dox. Tumors were harvested 24 hrs. following Dox treatment. For smart nanoparticles efficiency *in vivo*, mice bearing $\sim 200 \text{ mm}^3$ 231-2b tumors weight matched animals were randomly assigned into groups and injected with control or smart nanoparticles. At the endpoint, RNA and protein lysates were prepared from isolated tumors.

Bioluminescent imaging (BLI)

150 mg/kg luciferin (Perkin Elmer Inc.) was administered to mice intraperitoneally and mice were imaged as described previously (16).

Spontaneous metastatic tumor studies

2×10^6 4T1 or 231-2b cells were injected into the inguinal mammary fat pad or right flank of 6 to 8-week-old female Balb/cJ or NSG mice and tumor growth was monitored as previously

described (9). Where indicated, primary tumors were resected and animals were allowed to develop lung metastases. Mice bearing TNBC tumors were weight matched and randomly assigned into groups that received 1.2 mg/kg smart or control nanoparticles at the indicated times. The lung metastases in the animals were monitored by BLI. At the termination of the experiment, animals were euthanized and indicated tissues were harvested and processed for histological examination and immunohistochemical staining or for qRT-PCR analysis. Metastatic burden was calculated either as the number of visible metastatic lesion in each organ or as the relative luminescence signal from gross organ tissue.

Experimental metastasis *in vivo*

3×10^5 231-2b cells were inoculated directly into the left cardiac ventricle. Metastatic growth was monitored using BLI. Lungs, liver, femurs and brains were harvested post-mortem and processed for histological examination and gross analysis.

Bioinformatic analysis

cBioPortal was used to obtain TCGA expression z-scores for genes in Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort (18). FireBrowse (Broad Institute) was used to obtain normal breast tissue expression z-scores. Cooccurrence and mutual exclusivity analysis were performed with cBioPortal. Hazard ratios were assessed with Cox proportional hazard model for which TNBC and non-TNBC patients were stratified into high- and low-TRIM37 as third and first quartile. For Kaplan-Meier analysis, the p-value was calculated with log-rank test. For boxplot analysis, TRIM37-regulated genes were stratified according to TRIM37 expression using z score thresholds ($z > 0.5$, $z < -0.5$).

Statistical analysis

All experiments were performed at least in triplicate and the results presented are the mean of at least three different biological replicates. The comparisons between the two groups were done by unpaired *t*-test; comparisons between multiple treatment groups were done by one-way or two-way ANOVA with indicated multiple comparisons *post hoc* tests. The enrichment of genes positively correlating with TRIM37 were calculated with two-tailed Fisher's exact test. The distributions in correlation between GO terms was calculated by Kolmogorov-Smirnov test. All statistical analyses were performed using R/Bioconductor (version 2.15.2).

Results

TRIM37 associates with double strand break (DSB) repair machinery in TNBC

Several observations provided a rationale to explore the potential role of TRIM37 in promoting resistance to chemotherapeutic drugs that induce high level of DNA damage. TRIM37 catalyzes mono-ubiquitination of H2A (9), a chromatin modification enriched at transcriptionally repressed gene promoters (19) as well as at DNA damage sites (20). Furthermore, our analysis of the METABRIC cohorts revealed TRIM37 association with DNA repair genes (Fig.1A, Supplemental Table I), which was significantly stronger than genes involved in cellular proliferation (Supplementary Fig.1A, Supplemental Table I). Double strand break (DSB) repair is one of the major pathways to repair damaged DNA in

cancer cells and its kinetics predicts resistance to therapy (21,22). We therefore limited the analysis to repair proteins that participate in homologous recombination (HR) and non-homologous end-joining repair pathways (NHEJ), the two subtypes of DSB repair. RAD51C, XRCC5 (Ku80), RNF8, XRCC6BP1 (Ku70 binding protein), RNF168 and MRE11 were among the DSB genes whose expression most strongly associated with TRIM37 (Fig.1A). RAD51-associated proteins generally promote HR repair (23). XRCC5 and XRCC6BP1 are involved in NHEJ repair pathway (23). MRE11 forms complex with NBS1 and RAD50 to regulate response at DSB (24). RNF8 and RNF168 are E3 ligases that promote binding of DSB genes (23). Additionally, TRIM37 also correlated with the overexpression of a family of other DSB factors, including RAD51AP1, SFR1, DDX1, RAD51, ERCC1 and CHEK2. Together, these findings identified 28 DSB genes that significantly correlated with TRIM37 in breast cancer patients (Pearson's coefficient > 0.2; Supplemental Table I).

The analysis of METABRIC cohorts stratified by breast cancer subtypes revealed statistically significant correlation between TRIM37 and DSB genes in TNBC patients but not in non-TNBC patients or histologically normal breast tissue adjacent to tumor (NAT, Fig.1B and Supplementary Fig.1B). As shown in Fig.1C, the hazard ratio (HR) was ~2.3-fold higher for TNBC patients with high- compared to low-TRIM37 expression, linking TRIM37 to poor prognosis in TNBC patients. In contrast, no significant association between TRIM37 levels and survival was observed in non-TNBC patients (Fig.1D). Likewise, higher expression of a subset of DSB genes analyzed predicted poor overall-survival in TNBC patients as determined by HR > ~1 (Supplementary Fig.1C).

We next performed a series of functional experiments to determine the molecular mechanisms underlying the biological activity of TRIM37 in DSB repair using several human TNBC cell lines (HCC1806, MDA MB 468 and MDA MB 231; Supplementary Fig.1D). We first asked whether TRIM37 was physically associated with DSB genes. To test this idea, HCC1806 whole cell extract was fractionated by sucrose gradient sedimentation, and individual fractions were analyzed for TRIM37 and a representative subset of DSB proteins identified in Fig.1A. Results shown in Supplementary Fig.1E demonstrated that TRIM37 co-sediments with XRCC5, XRCC6, RAD51c, MRE11, and NBS1. Physical interactions between TRIM37 and DSB proteins could be confirmed by co-immunoprecipitation (Fig.1E and Supplementary Fig.1F) and immunofluorescence analysis (Supplementary Fig.1G) in MDA MB 468 cells treated with doxorubicin (Dox), a first-line chemotherapeutic agent. No significant changes in the expression of DSB genes were observed in HCC1806 cells expressing TRIM37-specific short hairpin RNA (shRNA), excluding TRIM37-mediated transcriptional regulation of these DSB genes (Supplementary Fig.1H–I, Supplemental Table II).

Prompted by these findings, we interrogated TRIM37 recruitment to DSB using two independent experimental systems. We first enzymatically-induced DSB at *Gapdh* using sequence-specific guide RNA (sgRNA) to promote Cas9-nuclease binding. Chromatin immunoprecipitation (ChIP) assay confirmed TRIM37 as well as H2Aub enrichment at the DSB in *Gapdh* (Fig.1F). Next, we analyzed recruitment of TRIM37 and BMI1, a component of the polycomb complex that participates in DSB repair (25), to the endogenous fragile site,

FRA3B. Consistently, CHIP analysis confirmed TRIM37 and BMI1 binding to *FRA3B* following Dox treatment (Fig.1G). In marked contrast to the control cells, knockdown of TRIM37 substantially decreased H2Aub enrichment as well as DSB proteins binding to *FRA3B* in Dox-treated MDA MB 468 cells (Fig.1H). As expected, repair efficiencies of NHEJ and HR pathways were significantly reduced in TRIM37-knockdown cells compared to control cells (Fig.1I). Together, these results demonstrate that TRIM37 interacts with DSB repair factors and functionally contributes to the repair of therapy-induced DNA damage.

TRIM37 catalyzed H2Aub is required for its function in chemoresistance

We next directly examined the impact of TRIM37-knockdown on chemotherapy-induced DNA damage and clonogenic growth. Knockdown of TRIM37 resulted in ~6-fold increase in median tail length in comet assay (Fig.2A and Supplementary Fig.1H,2A) and ~5-fold increase in the median nuclear coverage of phosphorylated histone H2AX (γ -H2AX, Fig.2B) in Dox-treated cells. TRIM37-knockdown in TNBC cell lines also markedly increased Caspase 3 activity and PARP cleavage (Fig.2C), hallmarks of cell death. By contrast, Dox-treated MCF7, a hormone receptor positive breast cancer cell line, did not augment PARP cleavage or Caspase 3 activity (Fig.2C), suggesting TRIM37 function in chemoresistance was limited to TNBC cells. As expected, knockdown of TRIM37 sensitized MDA MB 468 cells to chemotherapeutic stress without affecting proliferation as indicated by substantially decreased clonogenic growth relative to the control cells (Fig.2D and Supplementary Fig.2B).

Given ubiquitin is critical for DSB factor recruitment to damaged DNA (26), we next asked whether TRIM37-catalyzed H2Aub is required for its function in chemoresistance. To test this idea, we ectopically expressed either wild type TRIM37 (TRIM37) or catalytically-dead TRIM37 (TRIM37(C18R)) in MCF10AT, a premalignant K-RAS transformed triple negative breast cell line (Supplementary Fig.2C). While Dox-treatment induced significant enrichment of H2Aub at *FRA3B* in TRIM37 overexpressing cells, TRIM37(C18R) failed to promote H2Aub enrichment at *FRA3B* (Fig.2E). Consequentially, Dox-treatment of TRIM37(C18R)-expressing cells caused substantially longer comet tails (Fig.2F) as well as increased Caspase 3 activity (Fig.2G) and PARP cleavage (Fig.2H) relative to TRIM37-expressing cells. Finally, substantially fewer colonies were observed for cells expressing TRIM37(C18R) compared to TRIM37 following chemotherapeutic stress (Fig.2I and Supplementary Fig.2D).

TRIM37 promotes chemoresistance in the absence of functional p53

Wild type *TP53* represents a barrier to chemoresistance by altering DSB repair responses, activating checkpoints and the stress responses (27). Strikingly, TNBC tumors frequently harbor disrupting *TP53* mutations (Supplementary Fig.3A), which primarily cause the loss of its wild type function (28). Surprisingly, analysis of representative TRIM37-associated DSB genes showed a striking correlation between TRIM37 and DSB genes expression in TNBC patients carrying mutant *TP53* but not in wild type *TP53* (Fig.3A and Supplementary Fig.3B–D). Consistently, *TP53* mutant, but not wild type, TNBC patients with high-TRIM37 were at ~2.3-fold higher risk of death relative to low-TRIM37 (Fig.3B–C).

To investigate the relationship between p53 and TRIM37, we transiently expressed wild type p53 in MDA MB 468 (carries transcriptionally inactive p53 R273H) and HCC1806 (carries p53 T256Kfs*90 deletion) cells. For each cell line, p53-reconstituted TNBC cells showed significantly higher PARP cleavage (Fig.3D) and Caspase 3 activity (Fig.3E) compared to the control cells following Dox-treatment. A clonogenic assay confirmed that p53 over-expression sensitized MDA MB 468 (~4-fold) and HCC1806 (~2-fold) cells to Dox despite high levels of TRIM37 (Fig.3F and Supplementary Fig.3E). Reciprocally, ectopic expression of TRIM37 in genetically ablated p53 null (p53^{-/-}) MCF10A cells (14) substantially reduced PARP cleavage, and Caspase 3 activity relative to empty vector (Fig.3G–H). As expected, TRIM37-expressing p53^{-/-} MCF10A showed an ~4-fold increase in colony formation in comparison to control cells (Fig.3I and Supplementary Fig.3F). In summary, consistent with previous results for MDM2, KRAS, and ARID1 A (29), we find that TRIM37 requires loss of p53 to drive the chemoresistant phenotype in TNBC cells.

Chemotherapy amplifies a TRIM37 survival axis in TNBC

Most TNBC patients receive chemotherapy, which is effective in early stages of the disease but ~30–50% patients develop resistance (1). While the exact mechanisms of chemoresistance remain to be understood, chemotherapeutic drugs often induce genomic and transcriptomic reprogramming of resistant signatures (30), including alterations in DNA repair capacity (31). Previous studies have suggested that accumulation of such changes accompany selection and expansion of resistant TNBC cells (32). We therefore analyzed the expression of TRIM37 in MDA MB 468, HCC1806 and MDA MB 231 cells following chemotherapy. Surprisingly, we found that TRIM37 is upregulated in all the three TNBC cell lines tested in a time-dependent manner (Fig.4A). In contrast, no significant increase in TRIM37 was observed in p53 wild type MCF7 or MCF10A, an immortalized breast epithelial cell (Fig.4A). The analysis of TRIM37 upregulation kinetics in MCF7 and MCF10a revealed quick and robust p53 activation following Dox treatment (Supplementary Fig.4A), supporting our previous findings that p53 overrides TRIM37 function in chemoresistance (Fig.3). Indeed, ectopic expression of p53 in MDA MB 468 cells obliterated Dox-induced TRIM37 upregulation (Supplementary Fig.4B). As expected, TNBC cells treated with additional chemotherapeutic drugs also increased TRIM37 expression post-treatment (Fig.4B). Finally, increased *TRIM37* level in xenograft tumors following dox-treatment revealed therapy-induced transcriptional upregulation of TRIM37 *in vivo* (Fig.4C–D).

We next sought to determine the mechanistic basis for chemotherapy-induced burst in TRIM37 levels in TNBC tumors. A previous study identified TRIM37 association with ataxia-telangiectasia-mutated (ATM) kinase, a DNA damage sensor (33). Moreover, *TRIM37* promoter harbors regulatory elements for STAT and E2F1, downstream effectors of ATM kinase (Supplementary Fig.4C–E). We therefore investigated the potential role of ATM signaling in the transcriptional regulation of TRIM37 by utilizing small molecule inhibitors of either ATM or its downstream effectors, E2F1 and JAK (Fig.4E and Supplementary Fig.4F–J). JAK is a tyrosine kinase that phosphorylates STAT. qRT-PCR analysis revealed that pharmacological inhibition of ATM or its downstream effectors blocks *TRIM37* upregulation following Dox-treatment (Fig.4F). Similarly, E2F1- and STAT1/3-knockdown

abolished Dox-induced TRIM37 upregulation (Supplementary Fig.4K–L), whereas their overexpression significantly increased TRIM37 levels (Supplementary Fig.4M–N). ChIP analysis confirmed Dox-induced STAT1, STAT3, and E2F1 recruitment to *TRIM37*, which substantially decreased following pharmacological inhibition of JAK or E2F1 activation (Fig.4G–I). Consequently, inhibition of ATM signaling in MDA MB 468 cells induced significantly higher DNA damage and cell death relative to control cells as determined by γ -H2AX and PARP cleavage (Fig.4J).

Finally, to clinically validate chemotherapy-induced burst in TRIM37, we analyzed *TRIM37* expression in a panel of matched pre- and post-neoadjuvant chemotherapy-treated tumor biopsies from TNBC patients (see also Methods). qRT-PCR analysis showed that chemotherapy treatment increased *TRIM37* expression in ~82% of TNBC tumors carrying mutation in *TP53* (n=11, Fig.4K). Consistent with TNBC cellular models, no significant change in *TRIM37* was observed in *TP53*-wild type TNBC tumors (n=6; Fig.4K). Collectively, our results show that chemotherapeutic stress increases *TRIM37* expression in TNBC tumors in an ATM-dependent manner.

TRIM37 remodels transcriptional program favoring TNBC metastasis

While the emergence of chemoresistance is closely related to metastasis, the ability of a cancer cell to survive and proliferate under continuous standard chemotherapy does not warrant metastasis. Our analysis of previously published expression profiling of PDX mammary fat pad primary and corresponding lung metastatic tumors (34) revealed higher *TRIM37* in metastatic lesions (Supplementary Fig.5A). These results indicated that higher TRIM37 levels are maintained throughout the metastatic transition.

TRIM37 in association with polycomb complex alters gene expression to promote tumorigenesis (9). To test whether TRIM37 causes transcriptional misregulation of genes involved in metastasis, we knocked down TRIM37 in MDA-MB-231-D3H2LN-2b (35), hereafter referred to as 231-2b, using TRIM37-specific ASO (TRIM37-ASO, Supplementary Fig.5B) and performed transcriptomic analysis. Of the ~2,600 genes whose expression differed significantly between TRIM37-knockdown and control cells (GSE136617; Fig.5A–B), ~71 tumor and metastases suppressors, such as *KISS1* and *BRMS1*, were significantly down-regulated by TRIM37 (Supplemental Table III). As robust metastatic suppressors, *KISS1* and *BRMS1* reciprocally correlate with increased tumor recurrence, metastatic foci and reduced disease-free survival (36,37). The anti-metastatic function is mediated by altered gene expression through cell signaling pathways (38,39) as well as transcriptional regulation (40,41). Additionally, gene set enrichment analysis (GSEA) revealed that TRIM37-knockdown downregulates hypoxia, EMT transition, glycolysis, angiogenesis, inflammatory, and immune response-related genes in TNBC cells, indicating TRIM37-dependent activation of a pro-metastatic transcriptional program (Fig.5C and Supplementary Fig.5C). Likewise, KEGG pathway analysis identified TRIM37 target genes that associated with focal adhesion, pathways in cancer, actin cytoskeleton, ECM interaction, and signaling pathways (Supplementary Fig.5D).

To validate the RNA-seq results, we analyzed expression of representative genes in p53–/– MCF10A cells ectopically expressing TRIM37. Expression of *KISS1* and *BRMS1* was

significantly lower in cells ectopically expressing TRIM37 compared with empty vector (Fig.5D). Conversely, TRIM37-knockdown tumors expressed KISS1 and BRMS1 at significantly higher levels relative to control xenograft tumors (Fig.5E). To investigate the mechanism by which TRIM37 regulate KISS1 and BRMS1, we analyzed binding of polycomb complex components, BMI1 and EZH2, to *BRMS1* and *KISS1* by directed-ChIP assays. Both the gene promoters were enriched for BMI1 and EZH2 which was diminished after TRIM37 knockdown (Fig.5F). These gene promoters were also enriched for H2Aub, which was reduced after TRIM37 knockdown (Fig.5F). As expected, knockdown of BMI1 and EZH2 resulted in increased expression of these genes (Supplementary Fig.5E–F).

Our results raised the possibility that TRIM37-mediated repression of metastases suppressors induces transcriptional program favoring metastasis. To test this idea, we analyzed a representative set of 15 genes in the top GSEA categories based on statistical analysis and their known biological functions in multiple steps of metastasis (Supplemental Table IV). For all 15 genes analyzed, knockdown of BRMS1 or KISS1 resulted in their increased expression (Fig.5G–H and Supplementary Fig.5G). Consistently, ectopic expression of TRIM37 in p53^{-/-} MCF10A cells significantly increased expression of all the TRIM37 target genes compared with empty vector (Fig.5I), indicating reciprocal relationship between TRIM37 and metastases suppressors. To validate RNA-seq results *in vivo*, a subset of TRIM37 target genes were analyzed in TRIM37-knockdown tumors. As expected, all the 15 genes analyzed were significantly reduced in TRIM37-knockdown tumors relative to control tumors (Fig.5J). Moreover, knockdown of TRIM37 also decreased expression of TRIM37 target genes in MCF7 cells (Supplementary Fig.5H).

To investigate directly the potential function of TRIM37 in metastasis, we compared the *in vivo* propensity of control and TRIM37-knockdown cells in NSG mice (Fig.5K). Knockdown of TRIM37 showed dramatic reduction in the metastatic burden in comparison to control tumors that developed in sites comparable to human breast cancer metastases, such as the brain, lung, liver, lymph nodes, and bone (Fig.5L and Supplementary Fig.5I–J). TRIM37-knockdown reduced the metastatic tumor burden in lungs by ~2-fold, bone by ~2-fold, brain by ~3-fold, and liver by ~3-fold compared to the control animals 21-days after TNBC cell injection (Fig.5M). Further, histological analysis of tumors confirmed the distant tumor growth of the control and TRIM37-knockdown 231-2b cells in lung and liver (Supplementary Fig.5K). Finally, TRIM37-knockdown in 231-2b resulted in a modest but significant improvement of post-injection survival (Fig.5N). Collectively, these results demonstrate that TRIM37 overexpression enforces transcriptional program in TNBC tumors that promotes metastatic progression.

Design, construction and characterization of molecularly targeted nanoparticles to deliver TRIM37-ASO *in vivo*

We show that TRIM37 alters chromatin modification to resist chemotherapy and enforces changes in gene expression to favor metastatic transition. These results formed the underlying rationale for targeting TRIM37 as a therapeutic strategy for treating TNBC. To systematically assess the therapeutic effectiveness of inhibiting TRIM37, we engineered liposome-based nanoparticles consisting of DOPA, DOTAP, and DSPE-PEG2000-

Maleimide with TRIM37-ASO encapsulated in the core (see also Methods). We functionalized the nanoparticles by incorporating an investigational FOLR1 antibody (*Farletuzumab*). To this end, we site-specifically, and covalently conjugated DSPE-PEG2000-Maleimide to a cysteine-containing Fc-linkered sequence at the C-terminus of a *knob* heavy chain in *Farletuzumab* (Fig.6A and Supplementary Fig.6A–C). For convenience, these mono-disperse complexes are referred to as “smart nanoparticles” (Fig.6B and Supplementary Fig.6D). Fig.6C confirmed that ~67% of the maleimide groups present on the outer surface of the smart nanoparticles were functionalized with *Farletuzumab*. No significant differences in the binding affinity of Fc-linkered and monomeric *Farletuzumab* were observed (Fig.6D). As a control, we generated and characterized *Farletuzumab*-conjugated nanoparticles with control-ASO as a payload; hereafter, referred to as “control nanoparticles”. As expected, the diameter of 106 ± 21 nm (Fig.6E), and the overall charge of -4.72 ± 0.30 mV (Fig.6F) were not significantly different between smart and control nanoparticles.

Because higher levels of FOLR1 associate with advanced metastatic stage and recurrence in TNBC (42), we rationalized that smart nanoparticles will preferentially deliver TRIM37-ASO to TNBC cells. To test this idea, HCC1806RR (15) was co-cultured with either MCF7 or MCF10A cells (Fig.6G). Immunoblot analysis confirmed that FOLR1 is expressed at significantly higher levels in HCC1806RR compared to MCF7 or MCF10A cells (Supplementary Fig.6E). Interestingly, we observed ~100% uptake of IR800-labeled nanoparticles by TNBC cells compared to MCF7 or MCF10A cells post-mixing (Fig.6H–I). Finally, to test the TNBC cells selectivity of smart nanoparticles *in vivo*, we injected smart nanoparticles into the 231-2b xenograft-bearing mice. As expected, the smart nanoparticles selectively accumulated in the xenograft tumors within 24 hrs. and remained localized to the tumor up to 96 hrs. (Fig. 6J). The accumulation of smart nanoparticles in xenograft tumors was confirmed by the detailed tissue distribution using mice necropsies (Fig.6K).

Next, we evaluated the biological activity of the smart nanoparticles, which demonstrated sustained TRIM37-ASO release over a period of 48 hours with a biphasic release pattern (Supplementary Fig.6F). Treatment of MDA MB 231 cells with smart nanoparticles decreased *TRIM37* expression by ~80% in a time-dependent manner relative to control nanoparticles (Fig.6L). To investigate smart nanoparticles-mediated TRIM37 targeting *in vivo*, we challenged 231-2b-derived xenografts with smart nanoparticles. qRT-PCR and immunoblot analysis confirmed TRIM37 inhibition in smart nanoparticle-treated tumors compared to control nanoparticle-treated tumors (Fig.6M and Supplementary Fig.6G). Together, these results confirmed that smart nanoparticles-mediated delivery of TRIM37-ASO effectively decrease TRIM37 expression in TNBC tumors.

Targeting TRIM37 to prevent metastasis in TNBC

Next, we asked whether TRIM37 targeting will reduce metastatic lesions in syngeneic spontaneous metastasis murine model. To this end, Balb/c mice bearing mammary fat pad tumors derived from murine 4T1 cells were administered 1.2 mg/kg of control or smart nanoparticles (Fig.7A). To inhibit TRIM37, we utilized smart nanoparticles conjugated with murine cross-reactive anti-FOLR1 (Supplementary Fig.7A–C). While ~90% of the control

nanoparticle treated mice developed overt lung metastasis, smart nanoparticles-treated animals showed a dramatic decrease in lung metastasis, with ~60% of smart nanoparticles-treated animals showing no detectable lung metastases (Fig.7B and Supplementary Fig.7D). Animals were sacrificed at day 30 post-treatment due to the moribund condition of control nanoparticles-treated mice, which correlated with more rapid tumor growth at the primary and metastatic sites. The lung metastases were confirmed by H&E staining (Fig.7C and Supplementary Fig.7E), the gross lung tissue isolated post-mortem (Fig.7D–E), and a high proliferative index as determined by Ki67 staining (Fig.7F). Furthermore, TRIM37 was significantly reduced in the metastatic lesions isolated from the smart nanoparticle-treated animals compared to control animals (Supplementary Fig.7F). No significant changes in liver histology (Supplementary Fig.7G) or serum AST and ALT levels (Supplementary Fig.7H) between the control and smart nanoparticles-treated animals indicated a lack of hepatotoxicity.

Primary tumors are routinely treated with a combination of surgery and chemotherapy. Our findings revealed that TRIM37 augments the metastatic potential of TNBC tumors by promoting survival under chemotherapeutic stress, and by inducing metastatic effectors (summarized in Fig.7G). These results raised the possibility that combining TRIM37 inhibition with chemotherapy will simultaneously increase chemotherapy efficacy and prevent metastatic progression of TNBC to increase the overall survival in TNBC patients.

To test this idea in a clinically relevant setting, we generated primary tumors by subcutaneously implanting 231-2b lung-tropic cells in female NSG mice (Fig.7H). Animals were treated with either control or smart nanoparticles intranasally in combination with a single dose of 2 mg/kg of Dox intraperitoneally post-tumor resection. Significantly, animals treated with control nanoparticles developed lung metastases, whereas smart nanoparticles treatment dramatically reduced metastatic burden in the lungs (Fig.7I and Supplementary Fig.7I). H&E-stained lung sections (Fig.7J) and luciferase signals from gross lung tissues revealed ~5-fold decrease in metastatic growth in animals treated with smart nanoparticles compared to control nanoparticle treated animals (Fig.7K–L and Supplementary Fig.7J). Tumors from smart nanoparticles and Dox-treated animals showed decreased tumor growth as indicated by significantly higher staining for Caspase 3 (Fig.7M) and lower Ki67 staining (Supplementary Fig.7K) in lung metastatic tumors in comparison to the control tumors.

Discussion

This study identifies a new TRIM37 network, which is amplified by chemotherapeutic drugs, as a unifying mechanism that drives chemoresistant and metastatic phenotype in TNBC tumors. The results are relevant to ~80% of TNBC patients that lack functional p53 and rely on systemic chemotherapeutic treatments due to the unavailability of any targeted TNBC therapy.

Chemoresistance, in general, is accompanied with extensive genetic and epigenetic alterations. However, whether selection of the clonal cancer cells or new mutations drive chemoresistant phenotype remain to be resolved (32). A recent genomic and phenotypic evolution profiling of TNBC tumors identified both pre-existing resistant genotypes as well

as transcriptional reprogramming of resistant signatures in TNBC tumors (30). Our findings are in line with Kim et. al showing that pre-existing higher levels of TRIM37 in TNBC tumors promote resistance to chemotherapeutic stress and thus, increase survival of TNBC cells. On the other hand, chemotherapy triggers ATM signaling to transcriptionally upregulate TRIM37, which could further select for aggressive TNBC cells. In summary, TRIM37-positive TNBC tumors are protected and thrive under continued chemotherapy to cause aggressive metastatic disease.

A major hurdle in finding cure for aggressive TNBC is the lack of known drivers of the metastatic transition, in part due to a lack of mechanistic insights in the development of metastatic tumors. A genomics-driven discovery of recurring genetic mutations and epigenetic aberrations in the breast cancer genome has revealed tumorigenic drivers (6,43). However, whether these drivers that were primarily identified in the primary tumors are maintained throughout the chemotherapy regimen and the multistep process of metastasis remain to be evaluated. We used genomic and genetic approaches in relevant TNBC cellular, preclinical murine models and tumor biopsies to establish TRIM37 function in reducing therapy-induced DNA damage, increasing cancer cell survival, and causing transcriptional aberrations (Fig.7G). Our proof-of-concept results thus provide a rationale to target such common molecular effectors in combination with chemotherapy to prevent or significantly delay the metastatic progression in TNBC patients.

While targeted therapies are desperately needed to limit damage to healthy tissues, new delivery mechanism for cancer cell-specific targeting are also required to reduce detrimental side effects in healthy tissues. Molecularly targeted nanoparticles represent one such mechanism and are being aggressively explored for developing new treatment designs. As such, there are four nanoparticle-based therapies in clinical trials - BIND-014 for NSCLC and prostate cancer (44), CALAA-01 for solid tumors (45), SEL-068 for nicotine addiction (46), and Yale BNP for skin cancer (47).

Similar to mechanisms used in antibody-drug conjugates, we utilized a clinically investigative monoclonal antibody, which selectively delivers TRIM37-ASO into TNBC cells. The molecularly targeted nanoparticles offer a significant advantage over antibody-drug conjugates in terms of higher payload concentrations in tumor cells by enhancing retention times and permeability. An important consideration for nanoparticle delivery designs is clearance from the mononuclear phagocytic system. This is particularly critical for therapies designed to treat metastatic TNBC because premature elimination from circulation will prevent uptake by circulating tumor cells, decrease their accumulation in cancer cells and minimize their therapeutic impact. To overcome these issues, we incorporated PEG into our design, which enables steric stabilization of nanoparticles, and prevents interaction of the nanoparticles with immune cells (48). Functionalizing nanoparticles with “self” markers or homing molecules can further improve the systemic delivery of nanoparticles (49).

Notably, the majority of single-agent therapies tested to date for metastatic TNBC achieved an unimpressive response rate of less than 20%, with minimal impact on patient survival (50). The effective and selective delivery of TRIM37-ASO by *Farletuzumab*-conjugated

nanoparticles provides an excellent opportunity to test additional TNBC-enriched surface proteins using monoclonal or bi-specific antibody formats. Some of the targets that can be exploited include TNBC-enriched MUC1, Trop-2 and VEGFR2. Our results also raise the possibility that molecularly targeted nanoparticles can deliver diverse payloads selectively to cancer cells.

In conclusion, our results identify a new driver of metastatic progression in TNBC patients and provide a mechanistic link between the two clinically linked phenotypes: chemoresistance and metastasis. Our findings also raise the possibility of clinically targeting TRIM37 to diminish the resistance to therapy, reduce the dissemination of cancer cells, and infiltration of distant sites. We demonstrate that our therapeutic design selectively inhibits TRIM37 and attenuates metastatic progression of TNBC tumors *in vivo*.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Michael J. Lee, Michael R. Green, Takahiro Ochiya, David Weber, Michele Vitolo, and Sophia Ran for providing reagents; University of Virginia Tissue Histology Core, Biorepository and Tissue Research Facility (P30CA044579), Flow Cytometry Core (P30CA044579), Molecular Electron Microscopy Core, and The Office of Animal Welfare at University of Virginia. Edward Egelman, Ani W. Manichaikul, Marya Dunlap-Brown, and Stefan Bekiranov for technical and scientific discussion of statistical analysis. Christine Siu and Agnieszka Kokot for technical assistance with culturing cells. David Auble and Kristine Zengeler for editorial assistance. M.M. is supported by NCI RO1CA192399. J.T.S. is an Ovarian cancer Early Career Investigator. S.B. is the Hartwell investigator. S.B. is supported by Department of Defense Breast Cancer Research Breakthrough Award (BC170197P1, BC190343P1) and Metavivor Translational Research Award.

References:

1. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. *Breast Cancer Res Treat* 2011;125:627–36 [PubMed: 21161370]
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* 2007;109:1721–8 [PubMed: 17387718]
3. Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccion N, et al. Genomic characterization of metastatic breast cancers. *Nature* 2019;569:560–4 [PubMed: 31118521]
4. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. *Cancer Cell* 2017;32:169–84 e7 [PubMed: 28810143]
5. Ryan RJ, Bernstein BE. Molecular biology. Genetic events that shape the cancer epigenome. *Science* 2012;336:1513–4 [PubMed: 22723401]
6. Shen H, Laird PW. Interplay between the cancer genome and epigenome. *Cell* 2013;153:38–55 [PubMed: 23540689]
7. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature* 2012;486:400–4 [PubMed: 22722201]
8. Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. *Signal Transduct Target Ther* 2019;4:62 [PubMed: 31871779]

9. Bhatnagar S, Gazin C, Chamberlain L, Ou J, Zhu X, Tushir JS, et al. TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. *Nature* 2014;516:116–20 [PubMed: 25470042]
10. Bhatnagar S, Green MR. TRIMming down tumor suppressors in breast cancer. *Cell Cycle* 2015;14:1345–6 [PubMed: 25790001]
11. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. *Cell* 2017;168:670–91 [PubMed: 28187288]
12. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell* 2012;150:165–78 [PubMed: 22770218]
13. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. *Cancer Cell* 2009;15:9–20 [PubMed: 19111877]
14. Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, et al. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. *Oncogene* 2010;29:4715–24 [PubMed: 20562907]
15. Volk-Draper LD, Rajput S, Hall KL, Wilber A, Ran S. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. *Neoplasia* 2012;14:926–42 [PubMed: 23097627]
16. Shivange G, Urbanek K, Przanowski P, Perry JSA, Jones J, Haggart R, et al. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. *Cancer Cell* 2018;34:331–45 e11 [PubMed: 30107179]
17. Lou S, Zhao Z, Dezort M, Lohneis T, Zhang C. Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer. *ACS Omega* 2018;3:9210–9 [PubMed: 30197996]
18. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nat Commun* 2016;7:11479 [PubMed: 27161491]
19. Zhou W, Zhu P, Wang J, Pascual G, Ohgi KA, Lozach J, et al. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. *Mol Cell* 2008;29:69–80 [PubMed: 18206970]
20. Shanbhag NM, Rafalska-Metcalf IU, Balane-Bolivar C, Janicki SM, Greenberg RA. ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. *Cell* 2010;141:970–81 [PubMed: 20550933]
21. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. *Nature* 2012;481:287–94 [PubMed: 22258607]
22. Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. *Annu Rev Med* 2015;66:129–43 [PubMed: 25423595]
23. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol Cell* 2010;40:179–204 [PubMed: 20965415]
24. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. *Biochem Cell Biol* 2007;85:509–20 [PubMed: 17713585]
25. Ismail IH, Andrin C, McDonald D, Hendzel MJ. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. *J Cell Biol* 2010;191:45–60 [PubMed: 20921134]
26. Cohn MA, D'Andrea AD. Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. *Mol Cell* 2008;32:306–12 [PubMed: 18995829]
27. Kasthuber ER, Lowe SW. Putting p53 in Context. *Cell* 2017;170:1062–78 [PubMed: 28886379]
28. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. *Hum Mutat* 2003;21:301–6 [PubMed: 12619116]
29. Mina M, Raynaud F, Tavernari D, Battistello E, Sungalee S, Saghafinia S, et al. Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. *Cancer Cell* 2017;32:155–68 e6 [PubMed: 28756993]
30. Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. *Cell* 2018;173:879–93 e13 [PubMed: 29681456]

31. O'Connor MJ. Targeting the DNA Damage Response in Cancer. *Mol Cell* 2015;60:547–60 [PubMed: 26590714]
32. Navin NE. Tumor evolution in response to chemotherapy: phenotype versus genotype. *Cell Rep* 2014;6:417–9 [PubMed: 24529750]
33. Wu G, Song L, Zhu J, Hu Y, Cao L, Tan Z, et al. An ATM/TRIM37/NEMO Axis Counteracts Genotoxicity by Activating Nuclear-to-Cytoplasmic NF-kappaB Signaling. *Cancer Res* 2018;78:6399–412 [PubMed: 30254148]
34. Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. *Nat Commun* 2018;9:5079 [PubMed: 30498242]
35. Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. *Nat Commun* 2015;6:6716 [PubMed: 25828099]
36. Ulasov IV, Borovjagin AV, Timashev P, Cristofanili M, Welch DR. KISS1 in breast cancer progression and autophagy. *Cancer Metastasis Rev* 2019;38:493–506 [PubMed: 31705228]
37. Kodura MA, Souchelnytskyi S. Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases. *Cancer Metastasis Rev* 2015;34:611–8 [PubMed: 26328523]
38. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. *Cancer Res* 2005;65:3586–95 [PubMed: 15867352]
39. Wu P-Y, Yu I-S, Lin Y-C, Chang Y-T, Chen C-C, Lin K-H, et al. Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma. *Cancer Research* 2019;canres.3272.2018
40. Cicek M, Fukuyama R, Cicek MS, Sizemore S, Welch DR, Sizemore N, et al. BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. *Clin Exp Metastasis* 2009;26:229–37 [PubMed: 19165610]
41. Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, et al. Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. *J Biol Chem* 2008;283:7438–44 [PubMed: 18211900]
42. Ginter PS, McIntire PJ, Cui X, Irshaid L, Liu Y, Chen Z, et al. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. *Clin Breast Cancer* 2017;17:544–9 [PubMed: 28410844]
43. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70 [PubMed: 23000897]
44. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. *Int J Nanomedicine* 2014;9:467–83 [PubMed: 24531078]
45. Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. *Proc Natl Acad Sci U S A* 2014;111:11449–54 [PubMed: 25049380]
46. Desai RI, Bergman J. Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys. *Neuropsychopharmacology* 2015;40:2207–16 [PubMed: 25742871]
47. Deng Y, Ediriwickrema A, Yang F, Lewis J, Girardi M, Saltzman WM. A sunblock based on bioadhesive nanoparticles. *Nat Mater* 2015;14:1278–85 [PubMed: 26413985]
48. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv Drug Deliv Rev* 2016;99:28–51 [PubMed: 26456916]
49. Alqaraghuli HGJ, Kashanian S, Rafipour R. A Review on Targeting Nanoparticles for Breast Cancer. *Curr Pharm Biotechnol* 2019;20:1087–107 [PubMed: 31364513]
50. Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. *Oncotarget* 2017;8:106167–8 [PubMed: 29290935]

Significance:

TRIM37 drives aggressive TNBC biology by promoting resistance to chemotherapy and inducing a pro-metastatic transcriptional program; inhibition of TRIM37 increases chemotherapy efficacy and reduces metastasis risk in TNBC patients.




Figure 1: TRIM37 associates with DSB repair proteins in TNBC.

(A) Gene ranking of DNA repair genes according to cooccurrence with high-TRIM37 in breast cancer patients. The inset shows genes that have the highest correlation with TRIM37. A complete list of DNA repair genes that correlate with TRIM37 is presented in Supplemental Table I. (B) Heat map for the expression of TRIM37 and 28 DSB repair genes in breast cancer patients stratified by TNBC (n=299), non-TNBC (n=1605), and NAT (n=100). n, number of samples. (C-D) Forest plot of HR in TNBC (C) and non-TNBC (D) patients stratified for high- and low-TRIM37 expression using METABRIC cohorts. (E) Immunoblot monitoring XRCC5, XRCC6, NBS1, RAD51C, and TRIM37 in protein complexes pulled down by either anti-TRIM37 (Left), the indicated DSB proteins (Right), or an IgG control. Input, ~1–5% of whole cell lysates. (F) ChIP monitoring TRIM37 and H2Aub binding at *Gapdh* in MDA MB 468 cells expressing either Cas9 alone or with *Gapdh* site-specific sgRNA. (G) ChIP monitoring TRIM37 and BMI1 binding at *FRA3B*, *HOXA3*, and *Actin* in MDA MB 468 cells treated with doxorubicin (Dox). (H) ChIP monitoring H2Aub, XRCC5, XRCC6, NBS1, and RAD51c binding at *FRA3B* and *Actin* in MDA MB 468 cells expressing a non-silencer (NS) or TRIM37 shRNA. (I) HR (Left) and NHEJ (Right)-mediated DSB-repair activity in MDA MB 468 cells expressing control or TRIM37 shRNA (#1, #2). Error bars indicate standard deviation and range of at least three biological replicates. * p<0.05; ** p<0.01; *** p<0.001.




Figure 2. TRIM37-catalyzed H2Aub is required for chemoresistance in TNBC.

(A) *Top*, Tail moment in DMSO or Dox-treated MDA MB 468 cells expressing non-silencer (NS) or TRIM37 shRNA (#1, #2). *Bottom*, Representative images of the tails for each group are shown. Scale bars, 100 μ m. (B) *Top*, Quantification of γ -H2AX foci in MDA MB 468 cells expressing NS or TRIM37 shRNA (#1, #2) following treatment with Dox. *Bottom*, Representative immunofluorescence images of γ -H2AX foci (Green) in Dox-treated MDA MB 468 cells expressing NS or TRIM37 shRNA (#1, #2). DAPI (Blue) stains the nucleus. Scale bars, 50 μ m. (C) Caspase 3 activity assay (*Top*) and immunoblot for PARP and cleaved PARP (c-PARP) (*Middle*) in DMSO or Dox-treated MDA MB 468, MDA MB 231, and MCF7 cells expressing NS or TRIM37 shRNA (#1, #2). Quantification of PARP cleavage relative to total PARP is shown (*Bottom*). (D) Quantification of the fold change in chemotherapeutic drug-resistant colonies obtained for MDA MB 468 cells expressing either NS or TRIM37 shRNA (#1, #2) by a clonogenic assay. Cells were treated with DMSO, Dox, temozolomide (TMZ), etoposide (EPO), daunorubicin (Daun), and cisplatin (CPN). Results were normalized to the colony forming unit (cfu) for DMSO. (E) ChIP monitoring TRIM37 and H2Aub binding at *FAR3B* and *Actin* in MCF10AT cells expressing vector control (VC), TRIM37, or mutant TRIM37 (TRIM37(C18R)). (F) *Top*, Tail moment in DMSO or Dox-

treated VC-, TRIM37-, or TRIM37(C18R)-expressing MCF10AT cells. *Bottom*, Representative images of the tail moment for each group are shown. Scale bars, 100 μm . (G-H) Caspase 3 activity assay (G) and immunoblot for PARP and c-PARP (H, *Left*) in DMSO or Dox-treated VC, TRIM37 or TRIM37(C18R) expressing MCF10AT cells. Quantification of PARP cleavage relative to total PARP is shown (*Right*). (I) Quantification of the fold change in chemotherapeutic drug resistant colonies obtained for VC, TRIM37, or TRIM37(C18R) by clonogenic assay. Cells were treated with DMSO, Dox, temozolomide (TMZ), etoposide (EPO), daunorubicin (Daun), and cisplatin (CPN). Results were normalized to the cfu for DMSO. Error bars indicate standard deviation and range of at least three biological replicates. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.




Figure 3. TRIM37 reduces cytotoxicity of chemotherapy in the absence of functional p53.

(A) Heat map for expression of TRIM37 and DSB genes in TNBC patients stratified by *TP53* status (wild type (n=238) and mutant (n=61)). n, number of patients. (B-C) Forest plot of HR for TNBC patients with mutant *TP53* (B), or wild type *TP53* (C) stratified for high- and low-TRIM37 expression. (D) Immunoblots in Dox-treated MDA MB 468 and HCC1806 cells expressing NS, TRIM37 shRNA, or TP53. Tubulin is the loading control. *Bottom*, Quantification of c-PARP relative to total PARP. (E) Caspase 3 activity assay in Dox-treated MDA MB 468 and HCC1806 expressing NS, TRIM37 shRNA, or TP53. (F) Quantification of the fold change in cfu for Dox-treated MDA MB 468 and HCC1806 cells expressing NS, TRIM37 shRNA, or TP53 by clonogenic assay. (G) Immunoblots in Dox-treated p53^{-/-} MCF10A cells expressing TRIM37. Tubulin is the loading control. *Right*, Quantification of c-PARP relative to total PARP. (H) Caspase 3 activity assay in Dox-treated p53^{-/-} MCF10A cells expressing either vector control or TRIM37. (I) Quantification of the fold change in cfu for p53^{-/-} MCF10A cells expressing TRIM37 plated after Dox treatment by clonogenic assay. Error bars indicate standard deviation and range of at least three biological replicates. * p<0.05; ** p<0.01; *** p<0.001.




Figure 4. Chemotherapy amplifies oncogenic TRIM37 network in TNBC.

(A) *Top*, Immunoblots in MDA MB 468, HCC1806, MDA MB 231, MCF7, and MCF10A cells treated with Dox for 0, 24, 48 and 72 hrs. Tubulin is the loading control. *Bottom*, Quantification of TRIM37 relative to Tubulin. (B) Immunoblot monitoring TRIM37 in HCC1806 (*Top*) or MDA MB 231 (*Bottom*) cells treated with daunorubicin (Daun), cisplatin (CPN), etoposide (EPO) or temozolomide (TMZ). Tubulin is the loading control. *Right*, Quantification of TRIM37 relative to Tubulin. (C) Schematic showing that NSG mice were treated with intraperitoneal injection of 2 mg/kg Dox once tumor reached the size of ~200 mm³. Tumors were harvested postmortem. (D) qRT-PCR monitoring *TRIM37* expression in HCC1806 subcutaneous tumors-derived from NSG mice following treatment with Dox. n=6 animals per group. (E) Schematic of ATM signaling with the downstream effectors of ATM, E2F1, and STAT. Specific small molecule inhibitors of the ATM signaling are also indicated (*Red*). (F) qRT-PCR monitoring *TRIM37* expression in MDA MB 468 cells following treatment with KU55933, HLM006474 or AG490 in combination with Dox. (G-I) ChIP analysis monitoring the binding of E2F1 (G), STAT1 (H), and STAT3 (I) to *TRIM37* and *Actin* in MDA MB 468 cells treated with HLM006474 or AG490 in combination with Dox. (J) *Top*, Immunoblots in MDA MB 468 cells treated with Dox and the indicated inhibitors of ATM signaling. Tubulin is the loading control. *Bottom*, Quantification of TRIM37 relative to

Tubulin. (K) Heat map for *TRIM37* expression in mutant and wild type *TP53* TNBC tumor tissue samples pre- and post-chemotherapy. The type of *TP53* mutation is indicated on the right. NA, not available. (n = 17). Error bars indicate standard deviation and range of at least three biological replicates. * p<0.05; ** p<0.01; ***p<0.001.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. TRIM37 alters the transcription program to favor metastatic growth of TNBC tumors. (A) MA plot illustrates differential gene expression in TRIM37-ASO-treated compared to control 231-2b cells. Red are significantly upregulated genes ($n=1126$), blue are significantly downregulated genes ($n=1502$) and grey are genes not significantly changed ($n=12,440$). $FDR < 0.05$. (B) Hierarchical clustering of median-centered gene expression in control or TRIM37-ASO treated 231-2b cells. Each colored line in the dendrogram identifies a different gene. $n=3$ (C) Pathways significantly downregulated (*Blue*) or upregulated (*Red*) in TRIM37-ASO treated cells relative to control 231-2b cells identified by GSEA. (D-E) qRT-PCR monitoring TRIM37-regulated metastasis suppressor genes in TRIM37 overexpressing p53^{-/-} MCF10A cells relative to vector control (D) and TRIM37-ASO treated 231-2b tumors relative to control tumors (E). (F) ChIP monitoring BMI1, EZH2, TRIM37, and H2Aub binding at *KISS1*, *BRMS1*, and *Actin* in control and TRIM37-ASO treated 231-2b cells. (G-H) qRT-PCR monitoring TRIM37 target genes in 231-2b cells expressing KISS1 shRNA (G) and BRMS1 shRNA (H) relative to NS shRNA. (I-J) qRT-PCR monitoring TRIM37 target genes in TRIM37 overexpressing p53^{-/-} MCF10A cells relative to vector control (I) and TRIM37-ASO treated 231-2b tumors relative to control tumors (J). (K) Schematic showing that mice were injected with control or TRIM37-ASO treated 231-2b cells intracardially and monitored for metastatic tumor burden. $n=8$ animals per group. (L)

Representative ventral BLI of 231-2b expressing control or TRIM37-knockdown (TRIM37-ASO) at day 21. (M) Analysis of metastatic tumor growth in mice tissues measured by relative luciferase signal for lungs and number of metastatic lesions in lungs, bones, brain, and liver. n=8 animals per group. (N) Kaplan-Meier survival curve for mice injected with control or TRIM37-ASO-treated 231-2b cells. n=8 animals per group. Error bars indicate standard deviation and range of at least three biological replicates. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. Design, structural and functional characterization of smart nanoparticles in TNBC cellular and xenograft mouse models.

(A) A scheme of site-specific covalent conjugation of *Farletuzumab* to DSPE-PEG2000-Maleimide. An Fc-linked sequence harboring a *Cys* at the extended C-terminal hole chain in *Farletuzumab* and conjugated to DSPE-PEG2000-Maleimide. (B) Structural model of smart nanoparticles with TRIM37-ASO encapsulated in the core. (C) Density of *Farletuzumab* on smart nanoparticles (Smart NP). (D) Binding assay for relative avidity index of *Farletuzumab* or nanoparticles. (E-F) Dynamic light scattering (E) and zeta potential (F) for nanoparticles. (G) Schematic of co-culturing experiments described in (H-I). HCC1806RR (*Red*) and MCF7 or HCC1806RR (*Red*) and MCF10A cells were co-cultured and treated with the IR800-labeled smart nanoparticles. (H-I) Representative images for the uptake of smart nanoparticles by HCC1806RR co-cultured with either MCF7 or MCF10A as described in (G). Scale bars represent 50 μ m. Results are quantified (I). (J) Representative fluorescent images of tumor bearing mice after treatment with IR800-labeled smart nanoparticles at indicated times. The color scale depicts the fluorescence counts emitted from the tumor cells. (K) Necropsies from animals in (J) were analyzed by fluorescent imaging for detailed organ-specific distribution of IR800-labeled smart nanoparticles. (L) qRT-PCR monitoring expression of *TRIM37* in 231-2b cells treated with either TRIM37-ASO or control-ASO or nanoparticles for indicated times. (M) qRT-PCR monitoring expression of *TRIM37* in 231-2b tumors treated with control or smart

nanoparticles. Error bars indicate standard deviation and range of at least three biological replicates. n=6 animals per group. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 7. Targeting of TRIM37 suppresses metastatic lung tumors *in vivo*.

(A) Schematic showing that female Balb/c mice bearing mammary fat pad 4T1 tumors were treated with intranasal and intratumor injections of smart or control nanoparticles. n=8 animals per group. (B) Representative dorsal and ventral BLI images of tumor bearing mice at day 30 after treatment with either control or smart nanoparticles. The color scale depicts the luminescence counts emitted from the metastasis cells. n=4 animals per group. (C) Representative 10X H&E staining images of the lung metastases for control and smart nanoparticle treated animals. Scale bar, 0.5 mm. Arrows indicate lung metastatic nodules. (D) Lung necropsies from animals in (B) were analyzed by fluorescent imaging for tumor burden. (E) Quantification of metastasis incidence in the lung tissue after control or smart nanoparticles treatment. n=8 animals per group. (F) Ki67 staining of lung tumors derived from mice treated with control or smart nanoparticles. Scale bar, 0.5 mm. Arrows indicate highly proliferative lung metastatic nodules. (G) Model depicting TRIM37 function in

multiple steps of TNBC metastasis. (H) Schematic showing that NSG mice bearing subcutaneous 231-2b tumors were treated with intranasal injections of smart or control nanoparticles in combination with Dox post-tumor resection. n=8 animals per group. (I) Representative BLI images for tumor-bearing mice at day 1 and day 30 post-primary tumor resection. The color scale depicts the luminescence counts emitted from the metastasis cells. n=4 animals per group. (J) Representative 10X H&E staining images of the lung sections of control and smart nanoparticle treated animals. Scale bar, 0.5 mm. Arrows indicate lung metastatic nodules. (K) Lung necropsies from animals in (I) were analyzed for tumor burden. (L) Quantification of accumulated luciferase signal from the lung tissue after control and smart nanoparticles treatment. n=8 animals per group. (M) Caspase 3 staining of lung tumors derived from mice treated with control or smart nanoparticles in combination with Dox. Scale bar, 0.5 mm. Error bars indicate standard deviation and range of at least three biological replicates. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.